Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Paradigm Introduce Mouse Array

Premium

Agilent and Paradigm Genetics this week introduced a 60-mer oligo-based mouse microarray kit this week. The arrays are being produced as part of an on going collaboration between the Palo Alto, Calif.-microarray producer Agilent and Research Triangle Park, NC-based Paradigm, which holds a $23-million research contract for the National Institute of Environmental Health Sciences (NIEHS) and the Toxicogenomics Research Consortium.

The mouse array includes 22,575 mouse genes and transcripts as well as a set of toxicology markers in addition to the customizable section that Agilent includes on its oligo array products. The sequences used to design the probes are derived from public databases. Over 70 percent of the probes have been validated by Agilent.

The new array is complementary to a 14,000-probe development kit focusing on developmental genes in mice and introduced in 2002, Agilent said.

This latest launch might be part of a product development pattern the company is using to develop super-microarrays.

The company released its Human 1B microarray in June, and then in July told BioArray News of its plans to develop a single microarray combining the content of its 1A and 1B human genome microarrays.

“Internally we have the capability to print higher feature count microarrays that would be able to accommodate all known genes in the mouse genome,” said Hailing Sun, product manager for Agilent’s Bio-Research Solutions unit. “If the market wants a whole mouse genome, we certainly have the ability to make it and deliver it.”

—MOK

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.